Transcatheter Closure of Perimembranous Ventricular Septal Defect Using KONAR-MF™: A Multicenter Experience

被引:3
作者
Koneti, Nageswara Rao [1 ]
Azad, Sushil [2 ]
Bakhru, Shweta [1 ]
Dhulipudi, Bhargavi [1 ]
Sitaraman, Radhakrishnan [2 ]
Kumar, Raman Krishna [3 ]
机构
[1] Rainbow Childrens Heart Inst, Dept Pediat Cardiol, Plot 22,Rd : 10, Hyderabad 5000034, India
[2] Amrita Hosp Sect 88, Consultant Pediat Cardiol, Faridabad, India
[3] Amrita Inst Med Sci, Dept Pediat Cardiol, Kochi, India
关键词
Perimembranous ventricular septal defect; Transcatheter device closure; Occluder; KONAR-MF; Complete heart block; MEMBRANOUS VSD OCCLUDER; CHILDREN; DEVICE;
D O I
10.1007/s00246-024-03505-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Transcatheter closure of perimembranous ventricular septal defect (PmVSD) is an established procedure. However, the occurrence of complete heart block limits its scope. The newer KONAR-MF (TM) occluder has specific design characteristics that may improve the safety of PmVSD closure. The objective of the study was to describe the efficacy and mid-term follow-up of transcatheter closure of PmVSD using KONAR-MF (TM). The study was conducted prospectively in 3 Indian centers (January 2018-December 2022). PmVSD closure was done by both antegrade and retrograde methods, and patients were followed up at 1, 3, 6, 12 months, and annually after that. 121 out of 123 patients were included with the following characteristics: median age 4.4 (0.18-40) years; weight 15 (2.1-88) kg; mean Qp/Qs ratio 1.87 +/- 0.52 and pulmonary artery mean pressure: 22 +/- 6.9 mmHg. The procedure was successful in all but 3; the device was removed due to significant residual shunt (n = 2) and new development of aortic regurgitation (AR) (>= mild) in 1. The median defect size was 5.2 (2.5-12) mm. Device sizes from 6/4 to 14/12 were deployed (median fluoroscopy time 13.3 min; range 3.6-47.8). Shunt occlusion rates were 90%-Immediate, 95%-pre-discharge, and 97%-1 month, with no instances of complete heart block after the procedure and during follow-up. Six had new onset AR (mild: 2, trivial 4), and one had increased tricuspid regurgitation. All patients were well during follow-up (median: 20 months; range: 6-46). The new KONAR-MF (TM) occluder appears to be a promising and safe alternative for the closure of the PmVSD; further long-term follow is merited.
引用
收藏
页码:853 / 861
页数:9
相关论文
共 29 条
  • [1] MECHANISMS OF CLOSURE OF PERIMEMBRANOUS VENTRICULAR SEPTAL-DEFECT
    ANDERSON, RH
    LENOX, CC
    ZUBERBUHLER, JR
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1983, 52 (03) : 341 - 345
  • [2] Initial human experience with the Amplatzer perimembranous ventricular septal occluder device
    Bass, JL
    Kalra, GS
    Arora, R
    Masura, J
    Gavora, P
    Thanopoulos, BD
    Torres, W
    Sievert, H
    Carminati, M
    Fischer, G
    Ewert, P
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 58 (02) : 238 - 245
  • [3] Transcatheter closure of perimembranous ventricular septal defects - Early and long-term results
    Butera, Gianfranco
    Carminati, Mario
    Chessa, Massimo
    Piazza, Luciane
    Micheletti, Angelo
    Negura, Diana Gabriella
    Abella, Raul
    Giamberti, Alessandro
    Frigiola, Alessandro
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (12) : 1189 - 1195
  • [4] Transcatheter closure of congenital ventricular septal defects: results of the European Registry
    Carminati, Mario
    Butera, Gianfranco
    Chessa, Massimo
    De Giovanni, Joseph
    Fisher, Gunter
    Gewillig, Marc
    Peuster, Mathias
    Piechaud, Jean Francois
    Santoro, Giuseppe
    Sievert, Horst
    Spadoni, Isabella
    Walsh, Kevin
    [J]. EUROPEAN HEART JOURNAL, 2007, 28 (19) : 2361 - 2368
  • [5] Cohen MS., 2016, Moss and adams' heart disease in infants, children, and adolescents, V9, P783
  • [6] NATURAL-HISTORY OF VENTRICULAR SEPTAL-DEFECT - STUDY INVOLVING 790 CASES
    CORONE, P
    DOYON, F
    GAUDEAU, S
    GUERIN, F
    VERNANT, P
    DUCAM, H
    RUMEAUROUQUETTE, C
    GAUDEUL, P
    [J]. CIRCULATION, 1977, 55 (06) : 908 - 915
  • [7] Transcatheter Ventricular Septal Defect Closure with Lifetech™ Konar-MF Occluder in Infants Under 10 kg with Only Using Venous Access
    Ece, Ibrahim
    Bagrul, Denizhan
    Kavurt, Ahmet Vedat
    Terin, Harun
    Torun, Gulsah
    Koca, Serhat
    Gul, Ayse Esin Kibar
    [J]. PEDIATRIC CARDIOLOGY, 2024, 45 (01) : 175 - 183
  • [8] The Amplatzer® Membranous VSD Occluder and the vulnerability of the atrioventricular conduction system
    Fischer, Gunther
    Apostolopoulou, Sotiria C.
    Rammos, Spyros
    Schneider, Martin B.
    Bjornstad, Per G.
    Kramer, Hans Heiner
    [J]. CARDIOLOGY IN THE YOUNG, 2007, 17 (05) : 499 - 504
  • [9] Transcatheter closure of perimembranous ventricular septal defects using the new amplatzer membranous VSD occluder - Results of the US phase I trial
    Fu, YC
    Bass, J
    Amin, Z
    Radtke, W
    Cheatham, JP
    Hellenbrand, WE
    Balzer, D
    Cao, QL
    Hijazi, ZM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (02) : 319 - 325
  • [10] Percutaneous closure of restrictive-type perimembranous ventricular septal defect using the new KONAR multifunctional occluder: Midterm outcomes of the first middle-eastern experience
    Haddad, Raymond N.
    Daou, Linda S.
    Saliba, Zakhia S.
    [J]. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2020, 96 (03) : E295 - E302